Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report issued on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Stock Up 2.2 %

NASDAQ:PULM opened at $6.40 on Friday. The firm’s fifty day simple moving average is $4.69 and its 200-day simple moving average is $2.98. The stock has a market cap of $23.37 million, a PE ratio of -2.42 and a beta of 1.54. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $8.44.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.